Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-10-21
2003-05-13
Kunz, Gary (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S471000, C435S252300, C536S023500
Reexamination Certificate
active
06562591
ABSTRACT:
FIELD OF THE INVENTION
The present invention is directed to compositions involved in cell cycle regulation and methods of use. More particularly, the present invention is directed to genes encoding proteins and proteins involved in cell cycle regulation. Methods of use include use in assays screening for modulators of the cell cycle and use as therapeutics.
BACKGROUND OF THE INVENTION
Cells cycle through various stages of growth, starting with the M phase, where mitosis and cytoplasmic division (cytokinesis) occurs. The M phase is followed by the G1 phase, in which the cells resume a high rate of biosynthesis and growth. The S phase begins with DNA synthesis, and ends when the DNA content of the nucleus has doubled. The cell then enters G2 phase, which ends when mitosis starts, signaled by the appearance of condensed chromosomes. Terminally differentiated cells are arrested in the G1 phase, and no longer undergo cell division.
The hallmark of a malignant cell is uncontrolled proliferation. This phenotype is acquired through the accumulation of gene mutations, the majority of which promote passage through the cell cycle. Cancer cells ignore growth regulatory signals and remain committed to cell division. Classic oncogenes, such as ras, lead to inappropriate transition from G1 to S phase of the cell cycle, mimicking proliferative extracellular signals. Cell cycle checkpoint controls ensure faithful replication and segregation of the genome. The loss of cell cycle checkpoint control results in genomic instability, greatly accelerating the accumulation of mutations which drive malignant transformation. Thus, modulating cell cycle checkpoint pathways and other such pathways with therapeutic agents could exploit the differences between normal and tumor cells, both improving the selectivity of radio- and chemotherapy, and leading to novel cancer treatments. As another example, it would be useful to control entry into apoptosis.
On the other hand, it is also sometimes desirable to enhance proliferation of cells in a controlled manner. For example, proliferation of cells is useful in wound healing and where growth of tissue is desirable. Thus, identifying modulators which promote, enhance or deter the inhibition of proliferation is desirable.
Proteins of general interest that have been reported on include kinases. The Ste20 family of kinases can be divided into two structurally distinct subfamilies. The first subfamily contains a C-terminal catalytic domain and an N-terminal binding site for the small G proteins Rac1 and Cdc42 (Herskowitz,
Cell
, 80:187-197 (1995)). The yeast serine/threonine kinase Ste20 and its mammalian homologue, p21 Activated Kinase 1 (PAK1), belong to this subfamily. Ste20 initiates a mitogen-activated protein kinase (MAPK) cascade that includes Ste11 (MAPKKK), Ste7 (MAPKK), and FUS3/KSS1 (MAPK) in response to activation of the small G protein Cdc42, as well as signals from the hetero-trimeric G proteins coupled to pheromone receptors (Herskowitz,
Cell
, 80:187-197 (1995)). Similar to Ste20, PAK1 has been reported to be a Cdc42 and Rac1 effector molecule and specifically regulates the c-Jun N-terminal kinase (JNK) pathway, one of the mammalian MAPK pathways (Bagrodia, et. al.,
J. Biol. Chem
., 270:27995-27998 (1995); Kyriakis, et al.,
J. Biol. Chem
., 271:24313-24316 (1996)). The JNK pathway is activated by a variety of stress inducing agents, including osmotic and heat shock, UV irradiation, protein inhibitors and pro-inflammatory cytokines such as tumor necrosis factor (TNF) (Ip, et al.,
Curr. Opin. Cell Biol
., 10:205-219 (1998)). JNKs are activated through threonine and tyrosine phosphorylation by MEK4 and MEK7 (MAPKK), which are in turn phosphorylated and activated by MAPKKKs including MEK kinase 1 (MEKK1), and mixed lineage kinases MLK2 and MLK3 (Ip, et al.,
Curr. Opin. Cell Biol
., 10:205-219 (1998)). In addition to the activation of the JNK pathway, PAK1 has also been reported to be a regulator of the actin cytoskeleton (Sells, et al.,
Curr. Biol
., 7:202-210 (1997)).
The second subgroup of Ste20 family of kinases is represented by the family of germinal center kinases (GCK) (Kyriakis,
J. Biol. Chem
., 274:5259-5262 (1999)). In contrast to Ste20 and PAK1, GCK family members have an N-terminal kinase domain and a C-terminal regulatory region. Many GCK family members, including GCK, germinal center kinase related protein (GCKR), meatopoietic protein kinase (HPK) 1, GCK-like kinase (GLK), HPK/GCK-like kinase (HGK) and NCK interacting kinase (NIK), have also been reported to activate the JNK pathway when overexpressed in 293 cells (Pombo, et al.,
Nature
, 377:750-754 (1995); Shi, et al.,
J. Biol. Chem
., 272:32102-32107 (1997); Kiefer, et al.,
EMBO J
., 15:7013-7025 (1996); Diener, et al.,
Proc. Natl. Acad. Sci. USA
, 94:9687-9692 (1997); Yao, et al.,
J. Biol. Chem
., 274:2118-2125 (1999); Su, et al.,
EMBO J
., 16:1279-1290 (1997)). Among those, GCK and GCKR have been implicated in mediating TNF-induced JNK activation through TNF receptor associated factor 2 (Traf2) (Pombo, et al.,
Nature
, 377:750-754 (1995); Diener, et al.,
Proc. Natl. Acad. Sci. USA
, 94:9687-9692 (1997); Yuasa, et al.,
J. Biol. Chem
., 273:22681-22692 (1998)). NCK interacting kinase (NIK) interacts with the SH2-SH3 domain containing adapter protein NCK and has been proposed to link protein tyrosine kinase signals to JNK activation (Su, et al., EMBO J., 16:1279-1290 (1997)).
One study reports on a GCK family kinase from Dictyostelium that can phosphorylate Severin in vitro. (Eichinger, et al.,
J. Biol. Chem
., 273:12952-12959 (1998)). Severin is an F-actin fragmenting and capping enzyme that regulates Dictyostelium motility. However, there has not been any studies indicating the involvement of mammalian GCKs in cytoskeleton regulation.
Despite the desirability of identifying cell cycle components and modulators, there is a deficit in the field of such compounds. Accordingly, it would be advantageous to provide compositions and methods useful in screening for modulators of the cell cycle. It would also be advantageous to provide novel compositions which are involved in the cell cycle.
SUMMARY OF THE INVENTION
The present invention provides cell cycle proteins and nucleic acids which encode such proteins. Also provided are methods for screening for a bioactive agent capable of modulating the cell cycle. The method comprises combining a cell cycle protein and a candidate bioactive agent and a cell or a population of cells, and determining the effect on the cell in the presence and absence of the candidate agent. Therapeutics for regulating or modulating the cell cycle are also provided.
In one aspect, a recombinant nucleic acid encoding a cell cycle protein of the present invention comprises a nucleic acid that hybridizes under high stringency conditions to a sequence complementary to that set forth in
FIGS. 21
,
22
,
23
,
24
,
25
,
26
,
27
or
28
. In a preferred embodiment, the cell cycle protein provided herein binds to Traf2 or Nck. Most preferably, the cell cycle protein binds to Traf2 and binds to Nck.
In one embodiment, a recombinant nucleic acid is provided which comprises a nucleic acid sequence as set forth in
FIG. 21
(SEQ ID NO:1), 22 (SEQ ID NO:2), 23 (SEQ ID NO:3), 24 (SEQ ID NO:4), 25 (SEQ ID NO:5), 26 (SEQ ID NO:6), 27 (SEQ ID NO:7) or 28 (SEQ ID NO:8). In another embodiment, a recombinant nucleic acid encoding a cell cycle protein is provided which comprises a nucleic acid sequence having at least 85% sequence identity to a sequence as set forth in
FIG. 21
(SEQ ID NO:1), 22 (SEQ ID NO:2), 23 (SEQ ID NO:3), 24 (SEQ ID NO:4), 25 (SEQ ID NO:5), 26 (SEQ ID NO:6), 27 (SEQ ID NO:7) or 28 (SEQ ID NO:8). In a further embodiment, provided herein is a recombinant nucleic acid encoding an amino acid sequence as depicted in
FIG. 1
for Tnik, (SEQ ID NO:34) or
FIG. 29
(SEQ ID NO:9), 30 (SEQ ID NO: 10), 31 (SEQ ID NO: 11), 32 (SEQ ID NO: 12), 33 (SEQ ID NO:13), 34 (SEQ ID NO:14) or 35 (SEQ ID NO:15).
In another aspect of the invention, expression vectors ar
Fu C. Alan
Luo Ying
Shen Mary
Kunz Gary
Landsman Robert S.
Rigel Pharmaceuticals Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Germinal center kinase cell cycle proteins, compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Germinal center kinase cell cycle proteins, compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Germinal center kinase cell cycle proteins, compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3047254